Otezla was acquired by Amgen for $13.4 billion ... Last December, it secured FDA approval for the treatment of adult patients with plaque psoriasis, regardless of the severity of their symptoms ...

Otezla, a first-in-class treatment for plaque psoriasis has been approved in the US. Celgene's drug Otezla (apremilast) is an oral, selective inhibitor of phosphodiesterase 4 (PDE4) and gained its ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

Other drugs selected include Linzess to treat irritable bowel syndrome and chronic constipation, Vraylar to treat schizophrenia and major depressive disorder, Otezla to treat plaque psoriasis ...

In the U.S., Amgen recently launched Otezla for treating plaque psoriasis in children ages 6 and older. Argus has a “buy” rating and $360 price target for AMGN stock, which closed at $277.88 ...

No, the dosage of Zoryve is not similar to the dosage of Otezla (apremilast). While either drug may be prescribed to treat plaque psoriasis and other conditions, they come in different forms and ...

Amgen (NASDAQ:AMGN – Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on ...

Bimzelx (bimekizumab-bkzx) was approved by the FDA in October 2023 for the treatment of adults with moderate to severe plaque psoriasis who ... trial to compare it to Otezla was completed in ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...